Company Description

NAYA Biosciences, Inc. focuses on developing clinical and commercial-stage assets for fertility, oncology, and autoimmune diseases.

Its lead product includes NY-303, a GPC3-targeted FLEX-NK bispecific antibody that is in Phase I/II clinical trials for hepatocellular carcinoma; and NY-338, a CD38-targeted FLEX-NK bispecific antibody for multiple myeloma and autoimmune diseases.

The company also offers INVOcell, an IVC device that is an alternative to IVF that uses the female body for fertilization and incubation.

The company was formerly known as and changed its name to is based in Sarasota, Florida.

NAYA Biosciences, Inc.

Country	United States
Founded	2007
Industry	Medical/Nursing Services
Sector	Healthcare
CEO	Steven Shum

Contact Details

Address: 5582 Broadcast Court Sarasota, Florida 34240 United States
Phone	978-878-9505
Website	nayabiosciences.com

Stock Details

Ticker Symbol	NAYA
Exchange	NASDAQ
Reporting Currency	USD
CIK Code	0001417926
ISIN Number	US44984F4019
Employer ID	20-4036208
SIC Code	3841

Key Executives

Name	Position
Steven Shum	Chief Executive Officer
Andrea Goren	Chief Financial Officer
Anna Baran-Djokovic	Head of Investor Relations

Latest SEC Filings

Date	Type	Title
Nov 19, 2024	10-Q	Quarterly Report
Nov 19, 2024	10-Q/A	[Amend] Quarterly report
Nov 19, 2024	10-K/A	[Amend] Annual report
Nov 14, 2024	NT 10-Q	Notification of inability to timely file Form 10-Q or 10-QSB
Nov 13, 2024	SC 13G/A	[Amend] Statement of acquisition of beneficial ownership by individuals
Nov 8, 2024	8-K	Current Report
Oct 22, 2024	RW	Filing
Oct 15, 2024	8-K	Current Report
Oct 1, 2024	8-K	Current Report
Sep 20, 2024	8-K	Current Report

View All SEC Filings